A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India

Sponsor
Novo Nordisk A/S
Study ID
NCT01212133
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.

Study Details

This study is conducted in Asia. The aim of this study is to evaluate the safety and effectiveness of liraglutide in subjects with type 2 diabetes mellitus.

Key Dates

Start date
Nov 30, 2010
Status verified
Dec 2016
Primary completion
Apr 30, 2012
Completion
Apr 30, 2012

Study Design

Enrollment
1,386 participants (actual)

Arms

  • Arm: A

Primary Outcome Measure

The number of serious adverse drug reactions (SADRs) during the study period [ Time Frame: during 26 weeks of treatment ]

Related Studies